Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort

Affiliations


Abstract

Background: Predicting disease progression over time is challenging despite the available literature data.

Aim: To assess whether baseline clinical variables of MS patients would predict the conversion to progressive phase of the disease.

Materials & methods: Utilizing the national MS registry, patients who had relapsing onsets and had confirmed EDSS score at baseline and follow-up visits were included. Primary progressive MS and CIS patients were excluded. Clinical variables (gender, age at onset, disease duration, number of relapses, EDSS score) were collected. The end point was conversion to secondary progressive MS. Chi Square and multivariable logistic regression were used to determine the influence of clinical variables on disease progression.

Results: Data of 803 MS patients with relapsing onset were analyzed. Eighty five (10.6%) patients reached the end point. The risk of disease progression was significantly higher in men (p=0.015), in patients who developed MS≥40 years of age (p=0.041) and who had ≥3 relapses during their disease course (p<0.001). Spinal cord presentation at onset was predictive of progression (aOR=2.01; p=0.06) while optic neuritis at onset was associated with lower risk of progression (aOR=0.30; p=0.03). EDSS score at first visit did not influence disease progression when tested at 2 different cutoffs (EDSS<4 vs. ≥4 and EDSS<6 vs. ≥6) using multivariable logistic regression analysis (p=0.960 and p=0.866), respectively.

Conclusion: Men and patients who presented at age 40 yeas or beyond had increased risk of MS progression. Spinal cord symptoms at onset and 3 or more relapses were predictive of progression.

Keywords: Multiple sclerosis; gender; predictor; progression; spinal cord.


Similar articles

Predictive value of clinical characteristics for 'benign' multiple sclerosis.

Ramsaransing GS, De Keyser J.Eur J Neurol. 2007 Aug;14(8):885-9. doi: 10.1111/j.1468-1331.2007.01810.x.PMID: 17662009

Secondary progressive multiple sclerosis - clinical course and potential predictive factors.

Pokryszko-Dragan A, Gruszka E, Bilińska M, Dubik-Jezierzańska M.Neurol Neurochir Pol. 2008 Jan-Feb;42(1):6-11.PMID: 18365957

Natural history of multiple sclerosis: a unifying concept.

Confavreux C, Vukusic S.Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.PMID: 16415308

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.

Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM.Arch Neurol. 2006 Dec;63(12):1686-91. doi: 10.1001/archneur.63.12.1686.PMID: 17172607 Review.

Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.

Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C.PLoS One. 2014 Mar 20;9(3):e92761. doi: 10.1371/journal.pone.0092761. eCollection 2014.PMID: 24651401 Free PMC article. Review.


Cited by

Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.

van Schaik PEM, Zuhorn IS, Baron W.Int J Mol Sci. 2022 Jul 29;23(15):8418. doi: 10.3390/ijms23158418.PMID: 35955549 Free PMC article. Review.

Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.

Magyari M, Koch-Henriksen N.J Neurol Neurosurg Psychiatry. 2022 Jul;93(7):716-722. doi: 10.1136/jnnp-2022-328994. Epub 2022 Apr 7.PMID: 35393340 Free PMC article.

Determinants of disability development in patients with multiple sclerosis.

Kara F, Göl MF, Boz C.Arq Neuropsiquiatr. 2021 Jun;79(6):489-496. doi: 10.1590/0004-282X-ANP-2020-0338.PMID: 34320054 Free PMC article.

The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.

Yang T, Tian X, Chen CY, Ma LY, Zhou S, Li M, Wu Y, Zhou Y, Cui YM.Br J Clin Pharmacol. 2020 Apr;86(4):637-645. doi: 10.1111/bcp.14198. Epub 2020 Feb 8.PMID: 31869429 Free PMC article. Review.

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.

Tsivgoulis G, Katsanos AH, Mavridis D, Grigoriadis N, Dardiotis E, Heliopoulos I, Papathanasopoulos P, Karapanayiotides T, Kilidireas C, Hadjigeorgiou GM, Voumvourakis K; HELANI (Hellenic Academy of Neuroimmunology).PLoS One. 2016 Sep 29;11(9):e0163296. doi: 10.1371/journal.pone.0163296. eCollection 2016.PMID: 27684943 Free PMC article.


KMEL References